Genomics (4195) reported revenue of NT$42.4 million for Oct 2026, -12.8% year on year and -56.7% from the previous month. Revenue for Jan–Oct 2026 was NT$563.1 million (+4.9% year on year).
In Oct 2026, it ranked No. 104 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$42.4 million | -12.8% | -56.7% |
| Sep 2026 | NT$98.1 million | +69.1% | +94.5% |
| Aug 2026 | NT$50.4 million | -30.0% | -3.2% |
| Jul 2026 | NT$52.1 million | +8.5% | -27.8% |
| Jun 2026 | NT$72.1 million | +11.2% | +44.4% |
| May 2026 | NT$50 million | -28.2% | +8.2% |
| Apr 2026 | NT$46.2 million | -14.5% | -35.5% |
| Mar 2026 | NT$71.6 million | +30.9% | +91.9% |
| Feb 2026 | NT$37.3 million | -13.5% | -12.8% |
| Jan 2026 | NT$42.8 million | +79.3% | -61.6% |
| Dec 2025 | NT$111.5 million | +81.5% | +86.1% |
| Nov 2025 | NT$59.9 million | +12.8% | +23.0% |
| Oct 2025 | NT$48.7 million | +22.1% | -16.0% |
| Sep 2025 | NT$58 million | +12.1% | -19.5% |
| Aug 2025 | NT$72 million | +74.6% | +50.0% |
| Jul 2025 | NT$48 million | +19.3% | -26.0% |
| Jun 2025 | NT$64.9 million | +42.6% | -6.8% |
| May 2025 | NT$69.6 million | — | +28.9% |
| Apr 2025 | NT$54 million | — | -1.3% |
| Mar 2025 | NT$54.7 million | — | +26.9% |
| Feb 2025 | NT$43.1 million | — | +80.7% |
| Jan 2025 | NT$23.9 million | — | -61.1% |
| Dec 2024 | NT$61.4 million | +52.0% | +15.6% |
| Nov 2024 | NT$53.1 million | +46.4% | +33.1% |
| Oct 2024 | NT$39.9 million | +30.2% | -22.9% |
Jan–Oct 2026 cumulative: NT$563.1 million (+4.9% YoY)
Other Biotech & Medical companies
Compare with peers: Genomics vs PEC / Genomics vs Lotus Pharm / Genomics vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16